Company Profile

Rooted in the myth of Achilles, the name of Achillion refers to the brave warrior committed to a cause as well as the company's mission to combat diseases by identifying and exploiting their unique vulnerabilities.


Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is a science-driven, patient-focused company leveraging its strengths across the continuum from drug discovery to commercialization to provide better treatments for people with serious diseases.

... (more)

Stock Performance

Press Releases  [View all]

Dec 20, 2017
Achillion Initiates Phase I First-In-Human Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D

Dec 18, 2017
Achillion Announces ACH-4471 Granted Orphan Drug Designation for the Treatment of C3 Glomerulopathy (C3G) and the Initiation of a Phase 1 Extended-Release Bioavailability Study

Nov 15, 2017
Achillion Announces Pricing of Secondary Offering Of Common Stock

Nov 14, 2017
Achillion Announces Proposed Secondary Offering of Common Stock

Nov 14, 2017
Achillion Reports Preliminary Proof-of-Concept With ACH-4471 for the Treatment of C3G

Upcoming Events  [View all]

Feb 14, 2018 11:30 AM ET
LEERINK Partners 7th Annual Global Healthcare Conference

Financial Disclosures  [View all]

Third Quarter Financial Results
Feb 23, 2017
Annual Report (10-K)

Apr 17, 2017
Proxy Statement (DEF 14A)

Nov 1, 2017
Quarterly Report (10-Q)

Aug 8, 2017
Quarterly Report (10-Q)

May 4, 2017
Quarterly Report (10-Q)